Home › Compare › EVRZF vs ABBV
EVRZF yields 77.87% · ABBV yields 3.06%● Live data
📍 EVRZF pulled ahead of the other in Year 1
Combined, EVRZF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EVRZF + ABBV for your $10,000?
EVRAZ plc, together with its subsidiaries, engages in the production and distribution of steel and related products in Russia, the Americas, Asia, Europe, CIS, Africa, and internationally. It operates through four segments: Steel; Steel, North America; Coal; and Other Operations. The company offers steel and value-added products, including infrastructure steel, rails, large-diameter pipes, and oil country tubular goods. It also extracts vanadium ores; processes and produces vanadium products; and mines and enriches iron ore and coal. In addition, the company engages in the energy-generating, shipping, and railway transportation businesses. It offers its products for use in infrastructure and construction projects; and rail, energy, and industrial end-user markets, as well as coke and steel producers. The company was formerly known as Project Savannah PLC and changed its name to EVRAZ plc in October 2011. EVRAZ plc was founded in 1992 and is based in London, the United Kingdom.
Full EVRZF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.